Chemed二季度电话会显示VITAS强劲并上调2026年指引，但信号发布时已接近美股收盘且属于财报日后复盘

Earnings Call Insights: Chemed Corporation (CHE) Q2 2026
Management View
- “VITAS' performance during the quarter exceeded even the high end of our expectations,” and “these factors combine to allow VITAS to achieve higher-than-expected revenue growth and EBITDA margins,” while “continuing to add cushion to the Medicare Cap position in our Florida combined program” (CEO, President & Director Kevin McNamara).
- “Admissions at VITAS during the quarter totaled 19,125 which equates to a 9% improvement from the same period of 2025,” and “hospital additions as a percent of total admissions for our Florida combined program were 42.9% during the second quarter of 2026” (CEO McNamara).
- “Improved admissions led VITAS to outperform our expectations while also adding $8.9 million to Cap cushion in the Florida combined program in the second quarter of 2026,” and “this strong performance makes us more confident than ever that VITAS has put the Florida Cap issue of 2025 behind us and has returned to a normalized rate of growth” (CEO McNamara).
- “In the second quarter, Roto-Rooter performed as we anticipated,” while “marketing costs and the independent contractor business continue to be a challenge,” and “lead generation and the resulting cost of customer acquisition remained a challenge” (CEO McNamara).
- “In June, Roto-Rooter purchased the territory and assets of franchises operating in South Texas, including Corpus Christi. The purchase price was approximately $12 million,” and “it is not expected to add a material amount of revenue or income in the last half of the year, but represents a nice growth opportunity for 2027 and beyond” (CEO McNamara).
- “Through the first 6 months of 2026, we have spent an aggregate total of $33.5 million, repurchasing 4 franchises in strategically advantageous locations,” and “we intend to continue to take advantage of those opportunities” (CEO McNamara).
- “VITAS net revenue was $443.3 million in the second quarter of 2026,” and “in the second quarter of 2026, VITAS accrued $500,000 in Medicare Cap billing limitation” (Executive VP, Controller, Principal Accounting Officer & CFO Michael Witzeman).
- “By the end of the second quarter, our total patient census exceeded 24,000 for the first time in VITAS history,” and “VITAS has never been in a better position to take advantage of growth opportunities” (Executive VP and President & CEO of VITAS Healthcare Joel Wherley).
Outlook
- “Full year ADC growth for 2026 is updated to a range of 5.75% to 6.25% compared to the previous guidance range of 4.5% to 5.5%,” and “anticipated revenue growth, excluding the impact of the Medicare Cap, improves from the previous guidance range of 6.5% to 7.5% to a revised range of 8.25% to 9.25%” (CFO Witzeman).
- “Revised EBITDA margin, excluding the impact of the Medicare Cap, is anticipated to be 19% to 19.5% compared to the previous guidance of 18% to 18.5%,” and “our anticipated full year Medicare Cap billing limitation is reduced to $7 million from our previous guidance of $9.5 million” (CFO Witzeman).
- “Full year guidance for the segment remains unchanged,” including “full year anticipated revenue growth is 3% to 3.5% for Roto-Rooter with an estimated adjusted EBITDA margin of 21.5% to 22.5%” (CFO Witzeman).
- “Full year 2026 earnings per diluted share... are estimated to be in the range of $25 to $25.75,” and “the revised 2026 guidance assumes an effective corporate tax rate on adjusted earnings of 24.5% and a diluted share count of 13.5 million shares” (CFO Witzeman).
Financial Results
- “The combination of the two business units drove an increase in total Chemed revenue of 8.8% and an increase in adjusted diluted earnings per share of 41.9% in the second quarter of 2026 as compared with the same period of 2025” (CEO McNamara).
- “The consolidated business generated cash flow from operations in excess of $173 million in the second quarter,” and management said this cash generation, “along with minimal leverage, allows us to pursue accretive acquisitions, aggressive share repurchases” (CEO McNamara).
- “Adjusted EBITDA, excluding Medicare Cap, totaled $80.6 million in the quarter,” and “adjusted EBITDA margin in the quarter, excluding Medicare Cap, was 18.2%” (CFO Witzeman).
- “Roto-Rooter branch residential revenue in the quarter totaled $159.1 million,” while “water restoration revenue declined 6.7%,” and “revenue from our independent contractors declined 1.9% in the second quarter of 2026” (CFO Witzeman).
- “Adjusted EBITDA for Roto-Rooter in the second quarter totaled $48.5 million,” and “the adjusted EBITDA margin in the quarter was 21.1%, which represents a 77 basis point decline from the second quarter of 2025” (CFO Witzeman).
Q&A
- Benjamin Hendrix, RBC Capital Markets: asked about VITAS long-term growth capacity and the 42%–45% hospital mix; Executive VP Wherley replied, “We absolutely believe it is very sustainable... we have no concerns whatsoever,” and CEO McNamara added, “we’re talking about double digit... traditional growth rates... in the double digits, the low double digits.”
- Benjamin Hendrix, RBC Capital Markets: asked about Roto-Rooter paid vs. free leads and SG&A; CFO Witzeman said, “we think that the situation is stable. It’s not deteriorating from here,” and CEO McNamara added, “we’re at the very least we’re in a new normal,” while also stating, “we want to do jobs. Every job we do at Roto-Rooter is profitable.”
- Brian Tanquilut, Jefferies: asked about VITAS margin drivers and sustainability beyond 2026; Executive VP Wherley said the “biggest driver” was balancing patient sources and that “we absolutely believe” longer-term margin sustainability, while CFO Witzeman added, “we’ve always had an internal benchmark... SG&A costs grow at half the rate of our revenue growth.”
- Brian Tanquilut, Jefferies: asked about expanding Roto-Rooter service offerings; CEO McNamara said prior expansions worked when “the cost of acquisition for that additional business is near 0,” and noted, “there’s nothing really at this point other than to say, yes, we’re investigating.”
- Joanna Gajuk, BofA Securities: pressed on how Roto-Rooter can hold guidance amid marketing costs; CFO Witzeman said, “Roto-Rooter missed their EBITDA by roughly $1 million... all marketing costs,” and “an extra $1 million of marketing costs is not enough to change our current or long-term outlook.”
- Joanna Gajuk, BofA Securities: asked about acquisition capacity and hospice CON/moratorium; CEO McNamara said, “I’d be very surprised if before the end of the year, we don’t make a nice Roto-Rooter acquisition,” while Executive VP Wherley said the moratorium “does not prevent us from moving forward with potential acquisition” if the provider has “been in service for 3 years and billing... for 3 years.”
- Joanna Gajuk, BofA Securities: asked if de novos are needed to manage Florida cap; Executive VP Wherley said de novos help but “gives us no concern going forward specific to cap management,” and added, “we’ve just recently broke ground on two new inpatient units that will come online in 2027.”
- Joanna Gajuk, BofA Securities: asked about the proposed rule and Florida reimbursement dynamics; Executive VP Wherley said, “national average, 2.4% in the proposed rule,” and “VITAS specifically, 1.9%, Florida is a little over 1% of an increase against the national average,” while management said integrity oversight focus was likely to increase but “we have no reason to believe... there would be significant or material reimbursement changes to the current structure.”
Sentiment Analysis
- Slightly negative analyst tone centered on sustainability (VITAS growth/margins), Roto-Rooter marketing pressure, acquisition availability, and hospice program integrity; questions repeatedly returned to “higher marketing costs” (Joanna Gajuk, BofA Securities) and long-term durability (Benjamin Hendrix, RBC Capital Markets; Brian Tanquilut, Jefferies).
- Slightly positive management tone in prepared remarks (VITAS outperformance, raised guidance) and more guarded on Roto-Rooter marketing; CFO Witzeman said, “we think that the situation is stable,” while also stating, “I would... hesitate to say... it’s going to significantly improve,” and CEO McNamara framed lead dynamics as “a new normal.”
- Compared with Q1, management language in Q2 increased emphasis on normalization and durability at VITAS (“more confident than ever”), while maintaining a consistent cautionary posture on paid-lead mix and Google-driven marketing costs at Roto-Rooter.
Quarter-over-Quarter Comparison
- VITAS guidance was raised again: Q2 increased 2026 ADC growth to 5.75%–6.25% from Q1’s 4.5%–5.5%, and increased 2026 EBITDA margin ex-cap to 19%–19.5% from 18%–18.5% (CFO Witzeman).
- Roto-Rooter guidance remained unchanged in Q2 after Q1 lowered the segment margin outlook versus original guidance; Q2 management kept describing marketing costs and contractor performance as ongoing challenges while highlighting operational offsets (collections, ancillary services, franchise acquisitions).
- Analysts’ Q2 questions broadened to include hospice moratorium mechanics and potential future reimbursement/oversight implications, whereas Q1 questions leaned more heavily on weather disruption, near-term marketing run-rate, and early impacts of CMS scrutiny in California.
Risks and Concerns
- “Marketing costs and the independent contractor business continue to be a challenge,” and “free leads generated from Internet searches declined 13.1%” with a higher paid-lead mix (CEO McNamara).
- Management flagged uncertainty around Internet platforms while describing mitigation as diversifying lead sources; CFO Witzeman said, “we’re trying to minimize our reliance on Google,” and CEO McNamara said, “the real win here is getting leads outside of the paid Google search.”
- On hospice oversight, management anticipated increased program integrity scrutiny but did not point to a specific reimbursement restructuring; Executive VP Wherley said, “we do expect there to be some elevated degree of program integrity oversight,” and “we have no reason to believe at this point that there would be an unbundling of the hospice benefit.”
Final Takeaway
Management attributed the quarter’s major swing factors to VITAS admissions strength, margin performance, and reduced Florida cap risk, and it raised full-year VITAS growth and margin expectations while lowering expected Medicare Cap billing limitation. Management kept Roto-Rooter’s full-year outlook unchanged and framed paid-lead and marketing-cost pressure as “a new normal,” emphasizing collections improvement efforts, ancillary service attachment, and continued franchise buybacks as offsets, while also indicating additional franchise acquisition activity could occur before year-end.
Read the full Earnings Call Transcript